Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Botulinum Toxin Accessory Proteins: Are They Just an Accessory?

View through CrossRef
BACKGROUND Botulinum neurotoxins produced by Clostridium botulinum consist of a complex of a core neurotoxin protein and one or more nontoxin accessory proteins. The accessory proteins are generally thought to protect the neurotoxin from the gastric environment in botulism poisoning, dissociating away upon absorption. Other than their questionable immunogenicity, they are rarely mentioned in botulinum toxin therapy. OBJECTIVE To review evidence that accessory proteins potentially play a role in neurotoxin activity. RESULTS Evidence suggests that the accessory proteins do not dissociate from the neurotoxin complex and enhance neurotoxin activity. Complexed type A botulinum toxin has dramatically higher endopeptidase activity than noncomplexed neurotoxin. A primary accessory protein, hemagglutinin-33, exhibits this same effect on both type A and type E core neurotoxin proteins, the latter not natively having this accessory protein. A clinical study using an objective computer assessment assay has shown a correlation between type A complex size and glabellar strain reduction, which reflects increasing clinical efficacy. Finally, a systematic review found no correlation between type A complex size and neutralizing antibody formation. CONCLUSION Accessory proteins may play a role in the efficacy of botulinum toxin and could remain complexed to the neurotoxin for longer than previously reported.
Ovid Technologies (Wolters Kluwer Health)
Title: Botulinum Toxin Accessory Proteins: Are They Just an Accessory?
Description:
BACKGROUND Botulinum neurotoxins produced by Clostridium botulinum consist of a complex of a core neurotoxin protein and one or more nontoxin accessory proteins.
The accessory proteins are generally thought to protect the neurotoxin from the gastric environment in botulism poisoning, dissociating away upon absorption.
Other than their questionable immunogenicity, they are rarely mentioned in botulinum toxin therapy.
OBJECTIVE To review evidence that accessory proteins potentially play a role in neurotoxin activity.
RESULTS Evidence suggests that the accessory proteins do not dissociate from the neurotoxin complex and enhance neurotoxin activity.
Complexed type A botulinum toxin has dramatically higher endopeptidase activity than noncomplexed neurotoxin.
A primary accessory protein, hemagglutinin-33, exhibits this same effect on both type A and type E core neurotoxin proteins, the latter not natively having this accessory protein.
A clinical study using an objective computer assessment assay has shown a correlation between type A complex size and glabellar strain reduction, which reflects increasing clinical efficacy.
Finally, a systematic review found no correlation between type A complex size and neutralizing antibody formation.
CONCLUSION Accessory proteins may play a role in the efficacy of botulinum toxin and could remain complexed to the neurotoxin for longer than previously reported.

Related Results

Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy
Introduction This article reviews the mechanism of action of botulinum toxin and provides an overview of its use in hand disorders relevant to hand therapy such as hyperhidrosis, s...
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Public perception and knowledge toward the non-cosmetic use of botulinum toxin in dermatology practices
Background: While botulinum toxin is widely known for its cosmetic applications, its therapeutic potential in dermatology remains under-recognized by the general public. This study...
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Antiarrhythmic properties of Botulinum toxin A: in vitro studies on human and rat cardiomyocytes
Abstract Botulinum toxin A is a well-known neurotransmitter inhibitor with a wide range of applications in modern medicine. In recent years, botulinum toxin preparations ha...
Therapeutic Potential of Botulinum Toxin in Hailey–Hailey Disease
Therapeutic Potential of Botulinum Toxin in Hailey–Hailey Disease
Background Hailey–Hailey disease (familial benign chronic pemphigus) is a rare autosomal dominant genodermatosis caused by ATP2C1 gene mutations, leading to def...
Observing Adverse Effects of Botulinum Toxin Injection in Cervical Dystonia Pateints
Observing Adverse Effects of Botulinum Toxin Injection in Cervical Dystonia Pateints
Background: Cervical dystonia is the most common adult onset focal dystonias and botulinum toxin injection is an effective treatment for this condition. Objective: The objective o...
7 th International Symposium on Enabling Technologies for Life Sciences (ETP)
7 th International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see Rapid Communications in Mass Spectrometry 2012, 26 , ...
Outcome of delayed versus immediate casting on spasticity of lower limb muscles in cerebral palsy post-botulinum toxin injection
Outcome of delayed versus immediate casting on spasticity of lower limb muscles in cerebral palsy post-botulinum toxin injection
Background: Botulinum toxin type A (BTX-A) is widely used to treat spasticity in children. The optimal strategy for the combined treatment of casting and BTX-A injections is not kn...

Back to Top